Page 101 - MSAM-3-3

CORRECTION

DOI: 10.36922/msam.corr081624
Published Online: August 20, 2024

Correction 1
Khan ZN, Albalawi HI, Valle-Pérez AU, et al. From 3D printed molds to bioprinted scaffolds: A hybrid material extrusion
and vat polymerization bioprinting approach for soft matter constructs. Mater Sci Add Manuf. 2022;1(1):7. doi: 10.18063/
msam.v1i1.7

The source and origin of the human mesenchymal stem cells (MSCs) used in the above-mentioned work were not
sufficiently declared in the methodology section. To amend this inadequacy, section 2.4 (Cell bioprinting and bioimaging)
was revised accordingly by adding the following:
“Human bone marrow mesenchymal stem cells (hBM-MSCs; hereinafter referred to as MSCs) employed in this study
were a kind gift from Professor Abdalla Awidi at the Cell Therapy Center of The University of Jordan (Jordan). The MSCs
used in this study are primary cells. The experimental protocols using the MSCs were approved by the institutional bioethics
committee of King Abdullah University of Science and Technology (KAUST) (#21IBEC023).”

This modification has been reflected and integrated directly in the latest version of record for this article, and a brief
statement flagging the modification made is displayed on the title page of said version of record.

Correction 2
Albalawi HI, Khan ZN, Rawas RH, Valle-Pérez AU, Abdelrahman S, Hauser CAE. 3D-Printed disposable nozzles for
cost-efficient extrusion-based 3D bioprinting. Mater Sci Add Manuf. 2023;2(1):52. doi: 10.36922/msam.52
The source and origin of the human neonatal dermal fibroblasts (HDFn) used in the above-mentioned work were not
sufficiently declared in the methodology section. To amend this inadequacy, the first sentence of the first paragraph in
section 2.5 (3D cell culture) was revised accordingly, as shown in the following:
“The biocompatibility of peptide hydrogel biomaterials of IVZK peptide was tested with human neonatal dermal
fibroblasts (HDFn; Cat. #C0045C, Gibco, USA).”
This modification has been reflected and integrated directly in the latest version of record for this article, and a brief
statement flagging the modification made is displayed on the title page of said version of record.

Correction 3

Jia Y, Abdelrahman S, Hauser CAE. Developing a sustainable resin for 3D printing in coral restoration. Mater Sci Add
Manuf. 2024;3(2):3125. doi: 10.36922/msam.3125

The source and origin of the human dermal fibroblasts (HDFs) used in the above-mentioned work were not sufficiently
declared in the methodology section. To amend this inadequacy, the first sentence of the second paragraph in section 2.2.6
(Cytotoxicity analysis) was revised accordingly, as shown in the following:
“Human neonatal dermal fibroblasts (HDFs; Cat. #C0045C, Gibco, USA) were selected as the most suitable cell type to
test the cytotoxicity of the printed material and investigate potential biomedical applications.”
This modification has been reflected and integrated directly in the latest version of record for this article, and a brief
statement flagging the modification made is displayed on the title page of said version of record.

Volume 3 Issue 3 (2024) 1 doi: 10.36922/msam.corr081624